Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin

使用人类 ES 衍生的胰腺 β 细胞生物打印新型 3D 组织，通过适当释放胰岛素来调节血糖

• 批准号: 520826-2017
• 负责人: Kieffer, Timothy
• 金额: $ 1.82万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640509
• 关键词: Bioprinting; novel; 3D; tissues; human

The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived betacells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasingcapability. The project represents a new collaboration between two leading Canadian technology developers:Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprintingtechnology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developedfor the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab willprovide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structuresusing Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized forcell viability, maturation, and insulin production in response to nutrients, both in vitro and following implantinto mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing theimmunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunityfor students in cutting edge biomedical engineering at the interface of academia and industry, and could lead tosubstantial investments in follow-up research and development.

该项目的目标是开发一种可植入的生物打印3D组织，该组织包含干细胞来源的β细胞，在管子网络中显示出高细胞活性和适当的胰岛素释放能力。该项目代表着两家领先的加拿大技术开发商之间的新合作：Aspect是一家总部位于温哥华的公司，专注于3D生物打印技术的开发和商业化，以及BC大学Timothy Kieffer博士的实验室，在那里已经开发了从人类胚胎干细胞生产胰岛素产生细胞的方案。Kieffer实验室将为已经分化为胰脏祖细胞或更多的人类ES细胞(向成熟的β细胞)提供Aspect，在那里它们将被Aspect生物打印成活的生物兼容的3D结构，使用Aspect独特的藻酸盐/胶原生物墨水。然后，在体外和植入小鼠体内后，生物打印的组织将严格表征强制活性、成熟度和胰岛素产生，以响应营养物质。随后的研究将探索改善移植物血管形成的策略，同时也将评估生物打印组织的免疫保护方面。该项目将为处于学术界和产业界交界处的尖端生物医学工程专业的学生提供一个极好的培训机会，并可能导致对后续研究和开发的实质性投资。